Rituximab in the treatment of bullous systemic lupus erythematosus

Journal of Clinical Rheumatology

Volumn 17, Issue 3, 2011, Pages 142-144

  Alsanafi, Shamael ^a,b,d   Kovarik, Carrie ^a,b   Mermelstein, Andrew L ^c   Werth, Victoria P ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Rheumatology Associates Ltd   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

bullous systemic lupus erythematosus; CD20 antibody; rituximab

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DAPSONE; HYDROXYCHLOROQUINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TETRACYCLINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AFRICAN AMERICAN; ANOREXIA; ARTICLE; BASEMENT MEMBRANE; BULLOUS SKIN DISEASE; BULLOUS SYSTEMIC LUPUS ERYTHEMATOSUS; CASE REPORT; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EPIDERMOLYSIS BULLOSA ACQUISITA; FEMALE; FEVER; HUMAN; HUMAN TISSUE; LEUKOPENIA; MUCOUS MEMBRANE PEMPHIGOID; MYALGIA; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RECURRENCE; SKIN; TREATMENT OUTCOME;

EID: 79955067178     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e318214f30c     Document Type: Article

References (13)

1. Fujimoto W, Hamada T, Yamada J, et al. Bullous systemic lupus erythematosus as an initial manifestation of SLE. J Dermatol. 2005; 32:1021-1027. (Pubitemid 43258831)
2. Yell JA, Allen J, Wojnarowska F, et al. Bullous systemic lupus erythematosus: revised criteria for diagnosis. Br J Dermatol. 1995; 132:921-928.
3. Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus. 2009;18:767-776.
4. Troiano M, Lotti T. Rituximab in dermatological diseases. G Ital Dermatol Venereol. 2009;144:495-499.
5. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6:859-866. (Pubitemid 44356635)
6. Liossis SN, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol. 2008; 127:280-285.
7. Maloney DG, Press OW. Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies. Oncology (Williston Park). 1998;12:63-76. (Pubitemid 28536400)
8. McDonald V, Leandro M. Rituximab in non-haematological disorders of adults and its mode of action. Br J Haematol. 2009; 146:233-246.
9. Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2673-2677. (Pubitemid 36118931)
10. Looney JR, Anolik J, Sanz I. A perspective on B-cellYtargeting therapy for SLE. Mod Rheumatol. 2010;20:1-10.
11. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus. Arthritis Rheum. 2010;62:222-233.
12. Looney RJ. B cell-Ytargeted therapies for systemic lupus erythematosus, an update on clinical trial data. Drugs. 2010;70:529-540.
13. Kolstad A, Holte H, Fossa A, et al. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximabYCHOEP-14 regimen. Hematologica. 2007;92:139-140. (Pubitemid 46232678)